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Abstract 
Altered fractionation radiotherapy for head and neck cancer has been associated with 
improved locoregional control, overall survival, and heightened toxicity compared with 
conventional treatment. Swallowing, nutrition and patient-perceived function for altered 
fractionation radiotherapy with concomitant boost (AFRT-CB) for T1-T3 oropharyngeal SCC 
has not been previously reported. Fourteen consecutive patients treated with AFRT-CB for 
oropharyngeal SCC were recruited from November 2006 to August 2009 in a tertiary hospital 
in Brisbane, Australia. Swallowing, nutrition and patient-perceived functional impact 
assessments were conducted pre-treatment, at 4-6 weeks post-treatment and at 6 months post-
treatment. Deterioration from pre-treatment to 4-6 weeks post-treatment in swallowing, 
nutrition and functional impact was evident, likely due to the heightened toxicity associated 
with AFRT-CB. There was significant improvement at 6 months post-treatment in functional 
swallowing, nutritional status, patient-perceived swallowing and overall function, consistent 
with recovery from acute toxicity. However, weight and patient-perception of their physical 
function and side effects remained significantly worse than pre-treatment scores. The ongoing 
deficits related to weight and patient-perceived outcomes at 6 months revealed this treatment 
has a long-term impact on function possibly related to the chronic effects of AFRT-CB.   
 
Key words: deglutition; deglutition disorders; nutrition; patient rated function; altered 
fractionation radiotherapy; oropharynx; squamous cell carcinoma 
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INTRODUCTION 
The use of altered fractionation radiotherapy (AFRT) for treatment of oropharyngeal cancer 
has demonstrated superiority in locoregional control and long-term survival when compared 
with conventionally fractionated radiotherapy1-3. AFRT with concomitant boost (AFRT-CB) 
delivers radiotherapy in an accelerated format without total dose reduction, resulting in 
heightened toxicity which may persist longer and result in a higher incidence of severe 
functional injury, including possible deleterious effects on swallowing and nutrition4-9. 
Anecdotal clinical evidence suggests that there is a more severe functional impact following 
AFRT-CB compared to conventional treatment; however as yet, there has been no detailed or 
systematic research investigating swallowing and nutrition outcomes following this treatment 
regimen. Consequently, the challenge ahead is to gain a better understanding of the nature of 
the dysphagia associated with new treatment modalities and the impact of this treatment 
modality on nutritional outcomes10. 
 
The majority of research studies to date that have investigated the functional outcomes of 
AFRT on swallowing and nutrition have been confounded by the concurrent use of 
chemotherapy11-17. With the known exacerbation of toxicity associated with combined 
chemotherapy and radiotherapy18, 19 it is not adequate to assume the functional results 
following combined AFRT plus chemotherapy treatment would be equivalent to receiving 
AFRT alone. Indeed, multimodality treatment has been shown to cause greater weight loss 
than single modality treatment regimens20  and more severe dysphagia presentation and 
aspiration risk11.  
 
Yu et al.8 have reported the only known study that examined swallowing outcomes and the 
impact on nutrition for a heterogenous head and neck cancer patient group treated with 
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intensive radiation protocols (i.e. accelerated with concomitant boost and accelerated 
hyperfractionation). They found that 18% of patients had developed swallowing dysfunction 
by 1-2 months post-treatment that was severe enough to require enteral feeding, with 
resolution of function for the majority (93%) of patients at 1 year post-treatment follow-up. 
However, their study was conducted as a retrospective chart review and used a simple rating 
scale to document swallowing status pre-treatment and at variable follow-up intervals (range 
= 3.7 to 66 months). Consequently, although the study provides preliminary evidence that 
negative swallowing outcomes appear to resolve in the long term for the majority of this 
population, the constraints in the study design did not allow for detailed description of the 
nature of swallowing dysfunction in the acute phase. The lack of systematic follow-up at set 
time intervals also limits the understanding of patterns of resolution, or possibly exacerbation, 
of swallowing and nutritional status over time. In addition, the heterogenous population 
studied with varying tumour sites further limits the interpretation of the results.  
  
Existing studies suggest swallowing and nutrition may be negatively impacted in head and 
neck cancer patients both before21, 22 and after existing modes of radiotherapy treatment11, 23-
25, although currently there is limited information regarding the status of patients within the 
head and neck cancer population who are receiving AFRT-CB alone. Although several 
studies have found improved survival with concurrent chemoradiotherapy protocols and a 
subsequent trend to treat in this manner, many patients are not deemed appropriate for this 
combined treatment and are still treated with radiotherapy alone 8, 26. This study aims to 
describe the nature, severity, and course of dysphagia, nutritional status and patient-perceived 
functional impact in individuals who undergo AFRT-CB for T1-T3 oropharyngeal SCC from 
pre-treatment to 6 months post-treatment. Thus, it remains clinically relevant to establish the 
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evidence base regarding the nature of the swallowing and nutritional outcomes that can be 
anticipated by patients undergoing altered fractionated regimens.  
 
MATERIALS AND METHODS 
Participants 
Participants were identified from consecutive presentations to the Princess Alexandra 
Hospital (PAH) Multidisciplinary Head and Neck Clinic, a large tertiary referral centre in 
Brisbane, Australia between November 2006 and August 2009. Only those patients with T1, 
T2, or T3 SCC of the oropharynx (tonsil, base of tongue [BOT], pharyngeal wall, or 
supraglottis) who were recommended for treatment with curative intent AFRT-CB were 
suitable for inclusion. Participants were ineligible if they had previously diagnosed head and 
neck cancer and/or treatment affecting the tonsil, BOT, pharyngeal wall, or supraglottis, 
and/or a pre-existing neurological or neurodegenerative condition that may have impacted on 
swallowing function. Patients with glottic SCC were excluded because the tumour location 
had the potential to impact on swallowing function and airway protection prior to treatment. 
 
During the study period, AFRT-CB was the recommended treatment for 17 patients, all of 
whom were eligible for recruitment. Of the eligible participants, two patients declined to 
participate, leaving a cohort of 15 participants who consented to involvement in the study. Of 
these, complete data sets were available for only 14 individuals as one participant (T1N2c left 
BOT, male, 70 years of age) died during treatment from causes unrelated to his cancer 
diagnosis. The remaining participants form the subject of this analysis. 
 
The cohort was predominantly male (12 male, 2 female) with a mean age of 66.4 years (SD = 
8.92; range = 53-82). Demographic and clinical characteristics are reported in Table 1. The 
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primary site of the tumour for the majority of participants was tonsil (n = 9, 64.3%), followed 
by supraglottis (n = 3, 21.4%). Fifty percent of participants had T2 tumours (28.6% T1; 
21.4% T3) and the majority of patients (64.3%) had no nodal disease (N0) (14.3% N1; 21.4% 
N2). Disease staging revealed that the majority of participants had stage III disease (35.7%), 
while in decreasing frequency of occurrence, 28.6% had stage II disease, 21.4% stage IV, and 
14.3% stage I disease. Half of the participants were ex-smokers and 85.7% reported being 
current alcohol drinkers. All patients received their treatment at the Metro South Radiation 
Oncology Service in Brisbane, Australia. Ethics approval was obtained from the Princess 
Alexandra Hospital and The University of Queensland Human Research and Ethics 
Committees. 
[insert table 1 near here] 
 
Procedure 
All participants underwent AFRT-CB in which a total dose of 66Gy was delivered in 35 
fractions within a schedule that employs a daily dose of 2Gy for five weeks, with a second 
daily dose of 1.6Gy (the concomitant boost) in the final 2 weeks of treatment, with at least 6 
hours interfraction interval. At pre-treatment, 4-6 weeks post-treatment, and at 6 months post-
treatment, participants underwent a range of assessments encompassing three areas: (1) 
swallow function, (2) nutritional status, and (3) global measures of the functional impact of 
head and neck cancer.   
 
Swallow Function 
Swallow function was evaluated at each assessment time point by a speech pathologist with 
more than 5 years experience with the head and neck oncology caseload using both a clinical 
swallowing examination and a videofluoroscopic assessment of swallowing. 
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The clinical examination of dysphagia included a compilation of medical history and 
discussions with the patient regarding side effects which were impacting on oral intake, 
followed by an oromotor assessment and subsequent trials of food and fluids as per standard 
protocols27. Food (full, soft, minced, pureed) and fluid (thin, mildly thick, moderately thick, 
extremely thick) consistencies were consistent with Australian standards28. From this 
assessment, the level of diet and fluids that could be managed safely without aspiration risk or 
excessive fatigue/pain was established.  In addition, a level of functional swallowing status 
was assigned using the Royal Brisbane Hospital Outcome Measure for Swallowing 
(RBHOMS)29, a 10-part validated outcome measure scale designed to measure everyday 
performance of swallowing function based on clinical indicators. The scale ranges from the 
most inferior swallowing status at level 1 (described as “patient aspirates secretions”), to level 
10, the highest functional status for swallowing outcome (described as “swallowing function 
at better than premorbid/preadmission level”)29. These levels map onto four functional stages: 
(A) Nil by mouth (levels 1-3), (B) Commencing oral intake (level 4), (C) Establishing oral 
intake (level 5-7), and (D) Maintaining oral intake (levels 8-10). 
  
Instrumental swallow examination was conducted via a videofluoroscopic swallow 
assessment (VFS), guided by a radiologist and speech pathologist. Participants were assessed 
in the lateral plane. The intent at each assessment session was to evaluate swallowing 
physiology on four fluid and three solid consistencies. A barium solution mixed at a ratio of 
100 grams of barium (E-Z-HD Barium Sulfate for Suspension 98% w/w Cat. No. 764) to 
65ml water was added to the three thickened liquids (pre-packaged Flavour Creations 
products in extremely thick, moderately thick, and mildly thick, 
www.flavourcreations.com.au) and coated onto the three solid (diced fruit, marshmallow, and 
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biscuit) consistencies. A barium solution mixed with water to a ratio of 50:50 was used to 
approximate thin fluids. A standard protocol was followed during the VFS procedures, and 
was discontinued only when participants aspirated greater than 90% of a bolus 
(approximated), were unable to clear a solid consistency without subsequent fluids (due to 
severe xerostomia), experienced severe pain or discomfort, or refused to continue the 
assessment. The protocol involved completing three mouthfuls of each consistency in the 
following sequence: extremely thick fluids, moderately thick fluids, mildly thick fluids, thin 
fluids, diced fruit, marshmallow and biscuit. It has been previously described that three trials 
per consistency are necessary to achieve 80% reliability30.  
 
Videofluoroscopic assessments were recorded onto video home system (VHS) cassettes and 
later converted onto digital video disc (DVD) using the MSI Digital@nywhere digital TV 
tuner Peripheral Component Interconnect (PCI) card and accompanying software (main 
interface version number 1.1.0.2). Video files were encoded as a Moving Picture Expert 
Group version 2 (MPEG2) video stream for analysis. Analysis of all VFS assessments was 
conducted by a single speech pathologist experienced in the procedure and evaluation of VFS 
assessments but not otherwise involved in the research study. The speech pathologist 
responsible for rating was provided with a compilation CD that contained all of the de-
identified VFS files presented in random order.  
 
The evaluation tools used for the VFS assessments included: (1) New Zealand Index for 
Multidisciplinary Evaluation of Swallowing (NZIMES)31, and (2) the Penetration-Aspiration 
Scale (PAS)32. The NZIMES is a comprehensive scale that can be used to assist in the 
physiological interpretation of VFS. Only four components of subscale one “Swallowing 
Physiology” which divides the analysis of swallowing function into five parameters (Oral, 
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Oral Pharyngeal Transit, Pharyngeal, Crico-esophageal and Laryngeal), was utilised in the 
current investigation. The fifth component, Laryngeal parameters, which measures 
penetration and aspiration events and airway response, was discarded in preference for the 
validated Penetration-Aspiration Scale discussed below. The four parameters used in this 
study have between two and five sections that further specify the anatomical and 
physiological components involved in the swallowing process. For example, Oral parameters 
is divided into labial closure, lingual control, palatal closure, and mastication. Each 
component is rated according to a five point descriptive scale where 0 equates to no 
significant impairment and 4 indicates a profound impairment.  
 
The scores from each physiological parameter of the NZIMES were interpreted individually 
and drawn from observations on all fluid and solid consistencies. There is no consensus on 
data reduction in VFS with some studies rating the first swallow33, rating the average 
performance across two or three swallows34-36, or giving no comment on the data analysis37, 
38. In the current study, the worst performance observed across the food and fluid trials was 
used for analysis.  Inter- and intrarater reliability was completed for this tool as reliability data 
have not been reported. Twenty percent of the VFS samples (n = 13) were randomly selected 
and compiled on to a CD for rating by a second experienced speech pathologist. In addition, 
intrarater reliability was calculated for the principle rater by requiring 20% of the samples (n 
= 8) to be re-rated no less than 3 months after the initial rating session.  Percent agreement 
within one rating point for inter- and intrarater reliability was 99.4% and 99.2%, respectively.  
 
The PAS32 was used to provide quantification of penetration and aspiration events observed 
during VFS. The PAS is an eight-point interval scale with documented high inter- and 
intrarater reliability that scores aspiration events according to the depth of material entering 
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the airway and whether this material is expelled from the airway32.  A rating of one (1) 
indicates material does not enter the airway, while a rating of eight (8) equates to material 
entering the airway and passing below the vocal folds, and no effort is made to eject.  
 
Nutritional Status 
Data collection on nutritional status at each time point was completed by an experienced 
dietitian who was a member of the Multidisciplinary Head and Neck Clinic. Measures used to 
evaluate nutritional status included (1) measurement of the participant’s weight, and (2) 
completion of the Patient-Generated Subjective Global Assessment (PG-SGA)39. A 
participant’s weight was recorded to the nearest 0.1 kg using digital scales (G-Tech 
International GL-6000), with all participants being assessed at the same location. A single 
height measurement was reported by patients as listed on their driver’s licence. Using this 
information, a body mass index (BMI) score was calculated using the standard formula: 
weight/height2 (kg/m2)40, 41. 
 
Nutritional outcomes were determined with the PG-SGA39. This assessment tool has been 
validated in the head and neck cancer population and is used extensively in clinical practice 
and clinical trials of nutrition intervention regimens42, 43. The PG-SGA comprises a patient 
completed section and a physical examination completed by a dietitian. The patient section is 
divided into four sections: weight, food intake, symptoms, and activities and function. 
Patients who experienced difficulty completing this independently were assisted by the 
dietitian in a structured interview format. The dietitian then completed three further sections: 
disease and its relation to nutritional requirements, metabolic demand, and a physical 
examination assessing fat stores, muscle status, and fluid status. The patient was rated 
globally as “well nourished” (PG-SGA A), “moderately malnourished” or “suspected of being 
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malnourished” (PG-SGA B), or “severely malnourished” (PG-SGA C). A numerical PG-SGA 
score was also calculated (range = 0 - 35) where a higher score is reflective of greater 
nutritional compromise, and scores greater than 9 are considered indicative of a critical need 
for nutritional intervention or symptom management39, 43.  
 
Global Measures of the Functional Impact of Head and Neck Cancer 
Following the swallowing and nutrition assessments, participants were also asked to complete 
a dysphagia-specific and a general functional impact questionnaire at the three time points. 
Participants were provided with the questionnaires to complete independently. If participants 
had difficulty with self-administration, the scale was completed in a structured interview 
format. 
 
Functional impact specifically related to dysphagia was assessed with the M.D. Anderson 
Dysphagia Inventory (MDADI)44. The MDADI is a validated and reliable questionnaire 
designed specifically to assess the functional impact of dysphagia in patients with head and 
neck cancer44. The MDADI consists of 20 items grouped under global, emotional, functional, 
and physical subscales. Patients rate each statement as “strongly disagree”, “disagree”, “no 
opinion”, “agree”, or “strongly agree”. These ratings are converted to numerical scores for 
analysis where strongly agree = 1 and strongly disagree = 5. The MDADI is scored by 
summing the rating from statements under each subscale, calculating the mean and 
multiplying that by 20 to give a total score between 0 (extremely low functioning) and 100 
(extremely high functioning). A global score is also obtained separately by asking the 
participant to rate the statement: “my swallowing ability limits my day to day activities” using 
the five-point scale described above. A number between 0 and 100 was calculated as above by 
multiplying the rating by 20. 
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General functional impact was measured using the Functional Assessment of Cancer Therapy 
Additional Concerns for Head and Neck version 4 (FACT-H&N)45. Comparison with the 
Performance Status Scale revealed that the FACT-H&N had moderately high internal validity 
and can differentiate patients according to overall performance status and treatment status 
using mean scores46. The FACT-H&N is a multidimensional self-reported tool with four core 
domains (27 individual items) examining physical, social/family, emotional and functional 
well being. Twelve additional items assess patient perceptions of treatment related side effects 
specifically for head and neck cancer 45, 47.  Patients were instructed to read the introductory 
statement prior to completing the scale. Once the patient had understood the directions for the 
questionnaire, they were instructed to complete all items by indicating how true each 
statement had been for them over the past 7 days using a five-point Likert scale, where 0 
equated to ‘not at all’ and 4 was ‘very much’. The FACT-H&N provides a score for each of 
the domains by summing the results of each item. A global score is calculated by adding each 
of the domain-specific results together with the additional concerns for head and neck cancer 
summed separately and added to the global score. Higher scores reflect superior quality of 
life45.  
 
Data Analysis 
Descriptive measures including means and standard deviations were recorded for all outcome 
measures. Non-parametric Friedman tests, with post-hoc Wilcoxon signed rank tests, were 
used to compare changes in the ordinal data collected for swallowing, PG-SGA numerical 
score, and functional impact across the three time points. Change between time points for the 
global measure of the PG-SGA (rated as A, B, or C) was measured using chi-square tests. 
One-way repeated measures ANOVA was used to record change over time points with ratio 
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data (weight) with repeated measures t-tests used for post-hoc comparisons. For all statistical 
comparisons, p<0.05 was taken to indicate statistical significance.  
 
RESULTS 
Swallow Function 
Analysis of diet level at each of the assessment stages revealed 78.6% of participants were 
tolerating a full diet and thin fluids pretreatment, and the remaining individuals had already 
made modifications to their diets, with 14.3% requiring a soft diet, and 6.7% a minced diet. 
Participants reported making these modifications due to pain related to their tumour, 
following biopsies, or difficulty chewing following pretreatment dental extractions. During 
and in the weeks following treatment, three patients received nasogastric tube (NGT) 
insertion. One patient received NGT insertion at week 3 of treatment (for 3 weeks), one at 
week 5 (for 3 weeks) and one was inserted one week post-completion of treatment (for 4 
weeks). By 4-6 weeks post-treatment, only 28.6% of participants were managing a full diet. 
For the remainder, 14.2% were tolerating thin fluids only (one patient receiving supplemental 
nasogastric feeding), 41.3% managing pureed consistencies, 14.3% minced, and 28.6% on a 
soft diet. Only one patient required mildly thick fluids, the remainder tolerated thin fluids. At 
the 6 month post-treatment time point, all patients were safely managing thin fluids; however 
only 43% had returned to a full diet, with the remainder (57%) only capable of managing a 
soft diet. Consistent with this pattern, statistical analysis for the RBHOMS scores revealed a 
significant change (X2 = 19.45, p < 0.001) across the pretreatment (M = 8.43, SD = 0.94), 4-6 
weeks post-treatment (M = 6.64, SD = 0.84) and 6 months post-treatment (M = 7.79, SD = 
0.43) time points. Post hoc analysis revealed a significant reduction in the level of swallow 
function at 4-6 weeks post treatment (z = -3.22, p < 0.001) compared to pretreatment. 
Between 4-6 weeks and 6 months post-treatment a significant improvement in functional level 
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(z = -3.03, p = 0.002) was observed; however levels at 6 months post treatment were still 
significantly lower than pre-treatment levels (z = -2.07, p = 0.04).  
  
Videofluoroscopy (NZIMES and PAS) 
As a cohort, statistical analysis revealed no significant change over time on any of the 
parameters evaluated by the NZIMES assessment (Table 2). This lack of statistical result was 
largely contributed to by high variability within the group and the fact that physiological 
deficits were identified both before and after treatment. To assist exploration of the main 
patterns of impairment in this population at each time point, the NZIMES scores were 
compressed into a binary scale where the parameters were reduced into “no impairment” 
(score of 0) versus “impairment” (score of > 0) (Table 3). Only those features that were 
observed in more than one third of the group (>33%) were considered noteworthy. This 
analysis revealed that at least one third of participants had some impairment in the Oral, Oral 
Pharyngeal Transit, Pharyngeal, and Cricoesophageal parameters at the pretreatment time 
point. Specific physiological impairment was observed in mastication, position of the bolus at 
the onset of the swallow, relative timing of the onset of the swallow, pharyngeal 
contraction/bolus propulsion, and laryngeal excursion (Table 3). By 4-6 weeks post-treatment, 
these physiological impairments were observed to persist and additional impairments in 
palatal closure, bolus propulsion through the UES, and clearance of pyriform sinus residual 
were observed. At 6 months post-treatment, there was no change in the areas of impairment.  
[insert table 2 & 3 near here] 
 
Analysis of penetration/aspiration ratings at each time point (Friedman test) revealed no 
significant change (X2 = 2.08, p = 0.35 for fluids, and X2 = 2.46, p = 0.29 for solids) across the 
pretreatment (M = 1.69, SD = 0.63), 4-6 week post-treatment (M = 2.31, SD = 1.55), and 6 
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months post-treatment (M = 2.08, SD = 1.85) time points. To assist in interpretation of group 
patterns over time, PAS ratings were classified into three broad categories of “no penetration 
or aspiration”, representing ratings 1 and 2; “penetration” representing ratings 3, 4, and 5; and 
“aspiration” representing ratings 6, 7, and 8. This analysis revealed that the majority of 
patients had no penetration or aspiration on fluids (92%) or solids (69%) at the pretreatment 
time point. At 4-6 weeks, there was a 20% increase in penetration and aspiration events on 
fluids. At 6 months, penetration and aspiration events improved for fluids (although not to 
pretreatment levels) but continued to worsen for solids (Table 4). There was greater 
penetration/aspiration of fluids at 4-6 weeks and for solids at 6 months post-treatment 
compared with any other time point. 
[insert table 4 near here] 
 
Nutrition 
Statistical analyses revealed significant change in weight and PG-SGA numerical scores over 
time (Table 5). Post-hoc repeated t-tests revealed significant weight loss at 4-6 weeks post-
treatment (t = 6.22, p <0.01), with mean weight loss greater than 10% total body mass 
compared with pretreatment scores. This significant weight loss from pretreatment continued 
at 6 months post-treatment (pre versus 6mths: t = 4.93, p <0.01), with a mean total weight loss 
of 14.2%. There was no significant change in weight between 4-6 weeks and 6 months (t = 
1.23, p = 0.24) post-treatment. BMI results followed the same pattern, deteriorating from a 
pretreatment mean of 26.9 kg/m2 (SD = 4.25) to 23.7 kg/m2 (SD = 3.28) at 4-6 weeks and 
23.0kg/m2 (SD = 3.54) at 6 months post-treatment. Similarly, the numerical score of the PG-
SGA revealed a significant increase (Z = -3.19, p <0.01) in nutritional compromise at 4-6 
weeks post-treatment compared to pretreatment. In contrast to weight and BMI, between 4-6 
weeks and 6 months there was a significant improvement (Z = -2.52, p = 0.01) in the PG-SGA 
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score, with the PG-SGA score at 6 months not significantly different from pretreatment levels 
(Z = -0.77, p = 0.44) (Table 5). The global rating of the PG-SGA (A, B, or C) revealed 
significant deterioration from pretreatment to 4-6 week post-treatment scores (X2 = 11.63, p = 
0.001, Fisher’s exact = 0.002), then significant improvement from 4-6 weeks to 6 months 
post-treatment (X2 = 9.14, p = 0.002, Fisher’s exact = 0.007). By 6 months the PG-SGA global 
rating revealed no significant difference between pretreatment and 6 months post-treatment 
scores (X2 = 0.24, p = 0.622, Fisher’s exact = 1.0). 
[insert table 5 near here] 
 
Participant-rated Functional Impact Questionnaires 
Analysis of the MDADI results revealed a significant difference across the three time points 
for the global and functional domains of swallowing (Table 6). Post hoc analysis revealed a 
significant deterioration in the 4-6 week post-treatment scores in both global and functional 
domains compared to those of pretreatment. Following treatment there was significant 
improvement from 4-6 weeks to 6 months post-treatment in the global domain. The functional 
domain revealed a similar pattern, although this was not statistically significant (Table 6). For 
both domains there was no statistically significant difference between pretreatment and 6 
months post-treatment scores. Regarding the emotional and physical domains, no significant 
difference was found between time points; however, a similar trend of deterioration at 4-6 
weeks with improvement (not to pretreatment levels) at 6 months was observed. 
    [insert table 6 near here] 
 
Statistically significant change across time was also observed in the overall scores as well as 
the physical, functional, and head and neck specific domains of the FACT-H&N (Table 6). 
Only the social/family and emotional components did not differ significantly across time 
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points. Post-hoc analyses revealed significant decline in the overall, physical, functional, head 
and neck specific scores at 4-6 weeks post-treatment compared with pretreatment scores. Two 
parameters (physical and head and neck specific) remained significantly lower than pre-
treatment scores at the 6 months post-treatment. There was significant improvement for the 
overall score and the physical and functional domains between 4-6 weeks and 6 months post-
treatment (Table 6). The head and neck specific domain did not change between the 4-6 week 
and the 6 month assessment, remaining significantly below baseline assessment.  
 
DISCUSSION 
Short-term and chronic side effects of organ preservation treatments for head and neck cancer 
with radiotherapy, with or without systemic therapy, have been documented to include 
dysphagia, nutritional compromise, and functional change. While radiotherapy treatment 
intensification has resulted in improved locoregional control, there have been reports of 
increased severity and duration of treatment-related toxicity4-9 which may impact on 
functional outcomes such as swallowing and nutrition. This study investigated the impact of 
one altered fractionation radiotherapy protocol (curative intent AFRT-CB) and found 
significant changes from pretreatment to 6 months post-treatment for swallowing, nutrition, 
and patient-perceived function. The current study revealed a trend for functionally preserved 
swallowing (some mild-moderate physiological impairment) prior to treatment that 
deteriorated at 4-6 weeks post-treatment, with the majority of patients requiring dietary 
modifications with concurrent significant negative change in weight.  Six months post-
treatment swallowing function was variable, with stabilisation in some areas and further 
deterioration in others, with weight stabilisation and improvement in overall nutritional status. 
There was also a significant detrimental impact on patient-perceived function related to 
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general everyday participation and swallowing function that did not improve to pretreatment 
levels at 6 months post-treatment.  
 
Pretreatment  
In the current study, the results of the clinical and instrumental swallowing assessments 
revealed patterns of performance that were consistent with those previously reported for the 
head and neck population in the literature.  The majority of patients exhibited a clinically 
functional swallow and were managing a normal diet prior to commencing treatment, with 
only a small proportion of the group requiring softer food consistencies due to pain or 
difficulty chewing. This is consistent with previous reports in heterogenous head and neck 
cancer populations where 75% of patients tolerated normal diets21, 22, 48, 49. Pretreatment 
physiological impairment observed on instrumental assessment was predominantly mild to 
moderate in severity in the study population. Oral phase deficits (mastication and timing/onset 
of the swallow) may be largely attributable to dental extractions and biopsies, reducing 
chewing efficiency and affecting oropharyngeal sensation leading to delayed onset of the 
pharyngeal swallow, as found by Pauloski, et al.21. The observed pharyngeal residue, 
pharyngeal transit times, and shorter UES opening durations in some individuals have also 
been observed previously in the literature21. Aspiration rates in our study population, noted 
predominantly on solid bolus trials, were also comparable to the rate of pretreatment 
aspiration (30%) found in oropharyngeal cancer patients by Stenson, et al.22.   
 
Four to Six Weeks Post-Treatment 
Treatment side effects have been reported as symptoms that lead to an inability to adequately 
maintain oral intake, necessitating nonoral supplementation or feeding50. Consistent with the 
findings of Yu et al.8, 21% received alternative feeding with NGT at this time point. The 
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current study shows that the majority of the patients treated with AFRT-CB experience 
swallowing complications at 4-6 weeks post treatment, with the significant deterioration in 
functional outcome a reflection of limitations in oral intake and reliance on texture-modified 
diets. AFRT-CB studies have documented the most severe reactions as occurring 5-7 weeks 
after commencing radiotherapy51, with the endpoint of acute reactions in altered fractionation 
regimens documented to be around the 4-6 week post-treatment point 1, 52-55.  
 
Physiologically, at 4-6 weeks post-treatment, functional swallow impairment was reflected in 
physiological deterioration across all parameters of the NZIMES: Oral (mastication and 
palatal closure), Pharyngeal (pharyngeal contraction/bolus propulsion and laryngeal 
excursion), and Crico-esophageal (bolus propulsion through the UES and clearance of 
pyriform sinus residue). The degree of penetration and aspiration events on fluids was also 
found to be greater than that at pretreatment. Therefore, oral phase impairment at this stage 
post treatment may have resulted from residual acute toxicity, namely, xerostomia and 
mucositis and subsequent oral ulceration, inflammation and pain impacting on patients’ 
ability to chew and effectively achieve tongue to palate closure56, 57. Ongoing oedema, pain, 
secretion, and sensation changes may have further affected efficient passage of the bolus and 
airway protection12, 58, 59. Observed deterioration across a large number of physiological 
parameters appears to reflect the impact of the large treatment field required for curative 
intent radiotherapy in oropharyngeal carcinoma with similar oropharyngeal structures targeted 
for most head and neck cancer patients to ensure adequate coverage of macroscopic disease 58-
60.  
 
Conversely, although still affecting more than one third of patients at the 4-6 week post-
treatment time point, there appeared to be physiological improvement in the Oropharyngeal 
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Transit parameter (both position of the bolus at the onset of the swallow and relative timing of 
the onset of the swallow components on the NZIMES). This improvement may reflect patient 
adjustment to managing oral intake without teeth. Equally though, a more prompt 
oropharyngeal transit may reflect pain, hypersensitivity and phagophobia61 which may have 
influenced the speed and timing of the swallow for some individuals at the 4-6 week post-
treatment time point. In the absence of pain ratings documented at the time of the VFS, we are 
unable the further elucidate the basis of this change in the Oral Pharyngeal Transit parameter. 
 
The significant mean weight loss, reduced BMI, and overall deteriorating nutritional status 
between pretreatment and 4-6 weeks post-treatment found in this study are similar to those 
prospective examinations that measure nutritional status in the heterogenous head and neck 
cancer population20, 43, 62 and mirror the deterioration in swallowing function. The limitations 
to swallowing caused by acute toxicity may have led to reduced oral intake which influenced 
weight and overall nutrition status. In the current cohort, the PG-SGA scores paralleled 
weight loss, which is similar to that of previous studies43, however peak difficulties in 
meeting nutritional requirements usually occurred prior to the 4-6 week post-treatment time 
point.   
 
Patient-rated swallowing and overall everyday function also deteriorated significantly at 4-6 
weeks post-treatment when compared with pretreatment scores. Acute toxicity related to 
treatment would appear to contribute to worse physical outcomes (i.e. reduced energy, 
increased pain, greater impact of side effects) and function (i.e. cooking, socialising, enjoying 
life/work) for the majority of patients. Similarly, symptoms specific to head and neck cancer, 
like taste and smell changes, dry mouth, sticky saliva, and coughing were significantly worse 
than pretreatment scores and have been described previously63. At this early stage, Örhn et 
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al.63 found 56% of patients reported that their oral symptoms had been a hindrance to 
everyday life, reflecting the global swallowing score found in the current AFRT-CB group.  
 
Six Months Post-Treatment  
At 6 months post-treatment, prolonged acute reactions to radiotherapy have usually settled 
and general improvement is expected1, as was observed with functional swallowing outcomes 
and tolerance of diet textures. At this time point the impact of chronic side effects on function 
is unclear; however, the current study observed both unchanging deficits and further 
deterioration in swallowing physiology, nutrition and patient-rated functional impact. 
Ongoing deficits may reflect a decline in early effects, where further deterioration in 
components may be a reflection of the onset of late effects, found to be significantly greater 
(for pharynx and salivary gland) in concomitant boost regimens when compared to standard 
fractionation1. 
 
Persistent deficits in swallowing physiology occurred in four physiological parameters from 
4-6 weeks to 6 months post-treatment, indicating that if there was no improvement in the 
period immediately following treatment, participants experienced impairment in that 
parameter for at least 6 months post-treatment, similar to findings in the chemoradiation 
literature15, 36, 37. Impairments of palatal closure, position of the bolus at the onset of the 
swallow, and laryngeal excursion have been found in the early post-treatment phase in 
chemoradiation patients with little functional improvement by 12 months post-treatment30, 58, 
60, and findings from the current study may suggest AFRT-CB causes similar long-term 
functional impairment. It has been proposed that the ongoing impairments in these 
components may be due to unhealed acute reactions giving rise to consequential late 
reactions, rather than true chronic impairments64, 65. 
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Deterioration in swallowing physiology up to 6 months post-treatment for mastication, 
pharyngeal contraction/bolus propulsion, bolus propulsion through the UES, and clearance of 
pyriform fossa residue also parallels patterns of physiological decline observed in the 
chemoradiation literature58, 66. Such changes have been attributed to chronic fibrotic changes 
affecting function of salivary glands, and range of movement of musculature and 
cartilage/bone12, 30, 67-72. Trismus and xerostomia are common post radiotherapy side effects 
for patients with head and neck cancer, and can deleteriously affect the ability to chew solid 
foods, manipulate solid boluses and prepare cohesive boluses ready for swallowing70, 71. 
Chronic fibrotic changes can also impact on the movement of structures in the pharynx, 
namely epiglottic deflection, pharyngeal contraction and UES opening, resulting in 
pharyngeal residue and subsequent aspiration 12, 30, 67, 69, 72, as seen in the current study.  
 
At 6 months post-treatment, mean weight remained relatively unchanged from 4-6 weeks, 
although overall nutrition (as scored by the PG-SGA) significantly improved reflecting the 
fact that, in general, nutrient intake was sufficient for weight stabilisation. Isenring et al.43 
report that although weight loss is a component of the overall nutritional status determined by 
the PG-SGA, it accounts for less than 10% of the score, thus accounting for this apparent 
discrepancy. Similar discrepancies have been reported by a number authors who found an 
increase in post-treatment intake did not correspond with increased weight20, 73 and was 
significantly associated with elevated resting energy expenditure74. Despite not returning to 
pretreatment weight, the absence of further weight loss by 6 months post-treatment is 
considered a positive outcome20 and has been previously reported in the head and neck 
literature43, 62, 75, 76.  
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In the current cohort at 6 months, there was significant improvement in both global 
swallowing and overall everyday function compared to 4-6 weeks post, moving toward 
pretreatment scores. Specifically, significant improvement was found for physical and 
functional components of performing everyday activities, as reported by Epstein and 
colleagues77 who found almost 60% of a heterogenous head and neck cancer population 
treated with surgery and/or radiotherapy reported no limitations at work or performing 
household jobs at 6-12 months post-treatment. As in the current study, negative outcomes at 6 
months have been reported for the physical and head and neck specific concerns, largely 
reflecting the ongoing trouble with swallowing, social eating, dry mouth, sticky saliva, and 
mouth opening in the irradiated population78, 79. In addition, weight loss of 10% or more in 6 
months, as found in the current study, has been associated with increased morbidity such as 
impaired wound healing, reduced immune function, and increased mortality, and has also 
been shown to impact on quality of life and functional outcomes80-83.  
 
While this is the first study to systematically examine swallowing, nutrition and patient-rated 
function longitudinally in patients undergoing AFRT-CB, the limitations of the current study 
are acknowledged. Firstly the small cohort numbers limit the statistical interpretation and 
generalisation of our results. The current research attempted to accrue a homogenous 
oropharyngeal patient population who were recommended for treatment with AFRT-CB. In 
doing so, the numbers of eligible participants were limited and disease staging variability 
increased among participants. Second, the follow-up period in this study was only until 6 
months post treatment. Several authors have found that as the time post-treatment lengthens 
patients’ quality of life improves. This may be a result of the resolution of tumour related 
symptoms or treatment side effects or improved patient adjustment to the ongoing deficits 
caused by head and neck cancer and its treatment, a pattern which emerged in the current 
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study44, 84-86. Such preliminary evidence may suggest that further improvements in functioning 
may be observed.  
 
CONCLUSION 
Patients with T1-T3 oropharyngeal cancer who are treated with curative intent using AFRT-
CB boost experienced significant functional swallowing and nutrition changes related to 
treatment. Patients with this type of cancer who undergo AFRT-CB also report significant 
negative functional impact that lasts up to 6 months post-treatment. Management of these 
patients requires multidisciplinary intervention from pretreatment to assess swallowing, 
nutrition and treatment related side effects. Education should be provided to these patients 
regarding the possible course of their treatment and recovery, so they are better prepared for 
the impact these deficits may have on their day to day functioning. Early discussion regarding 
the impact of acute side effects on swallowing and nutritional may help to limit the weight 
loss that many patients experience by increasing acceptance of symptom control and nutrition 
support measures. 
 
Future research needs to examine the functional outcomes of the relatively novel altered 
fractionation regimens for a longer time frame to determine the long-term functional 
outcomes of this population. In addition, this group should be compared with the more 
conclusively examined chemoradiation protocols to determine how swallowing and nutrition 
outcomes compare across treatment types. Future studies need to elucidate the duration and 
grading of acute toxicity until its resolution and its association with swallowing and nutrition 
impairment following non-surgical treatment for head and neck cancer. 
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Tables 
Table 1. Demographic details  
      
Participant 
Number 
 
Age Sexa TNMb classification and 
locationc 
Stage Smoking 
(current, 
ex, never) 
Alcohol 
(current, ex, 
never) 
01 82 M T1N0 L pharyngeal wall I Ex Current 
02 63 M T2N0 supraglottis II Current Current 
03 79 M T3N0 BOT  III Ex Current 
04 72 M T2N0 L tonsil  II Never Current 
05 69 F T2N2b L tonsil  IV Ex N/A 
06 73 M T2N0 L tonsil II Ex Ex 
07 70 M T1N0 L tonsil  I Ex Current 
08 69 M T2N1 R tonsil  III Ex Current 
09 69 M T3N0 R supraglottis III Current Current 
10 59 M T2N0 R supraglottis II Ex Current 
11 59 M T1N2a R tonsil IV Never Current 
12 58 F T3N0 R tonsil III Current Current 
13 53 M T2N1 R tonsil III Never Current 
14 54 M T1N2a R tonsil IV Never Current 
a M = male, F = female 
b T = T stage, N = N stage 
c L = left, R = right 
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Table 2. New Zealand Index for Multidisciplinary Evaluation of Swallowing (NZIMES) 
results 
 
NZIMES 
Parameter 
 Pre-
treatment  
 
m (SD) 
4-6 wks post-
treatment  
m (SD) 
6 mths post-
treatment  
m (SD) 
X2 
df = 2 
 
Friedman 
p 
 
Oral Labial Closure 0 0 0 0 0 
 Lingual Control 0.15 (0.38) 0.15 (0.38) 0.08 (0.28) 1.0 0.61 
 Palatal Closure 0.38 (0.65) 0.46 (0.52) 0.54 (0.66) 0.2 0.91 
 Mastication 0.85 (0.69) 1.15 (0.99) 1.46 (0.66) 2.47 0.29 
Oral Pharyngeal 
Transit 
Position of bolus at 
onset of swallow 
0.69 (0.48) 0.54 (0.78) 0.62 (0.87) 0.62 0.73 
 Relative timing of 
onset of swallow 
0.46 (0.52) 0.31 (0.48) 0.38 (0.51) 0.75 0.69 
Pharyngeal Velopharyngeal 
Closure 
0 0.23 (0.44) 0 6.0 0.05 
 Pharyngeal 
Contraction/Bolus 
Propulsion 
0.77 (0.83) 0.77 (0.6) 1.0 (0.58) 1.64 0.44 
 Laryngeal Excursion 0.54 (0.66) 0.54 (0.66) 0.46 (0.52) 0.29 0.87 
Crico-
esophageal 
Bolus Propulsion 
through UES 
0.31 (0.63) 0.31 (0.48) 0.54 (0.66) 0.89 0.64 
 Clearance of Pyriform 
Sinus Residual 
0.38 (0.65) 0.38 (0.51) 0.54 (0.66) 0.22 0.9 
 Upper Esophageal 
Parameters 
0 0 0 0 0 
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Table 3. Compressed videofluoroscopy data: “no impairment” versus “impairment” 
a Bold indicates 1/3 of group present with symptom 
 
  Pre-
treatment 
4-6 wks 
post-
treatment 
6 mths 
post-
treatment NZIMES  Parameter 
  % 
impairment 
% 
impairment 
% 
impairment 
Oral Labial Closure 0 0 0 
 Lingual Control 15 14 7 
 Palatal Closure 31 50a 50 
 Mastication 69 71 100 
Oral 
Pharyngeal 
Position of bolus at onset of 
swallow 
69 43 43 
 Relative timing of onset of 
swallow 
46 36 43 
Pharyngeal Velopharyngeal Closure 0 21  0 
 Pharyngeal Contraction/Bolus 
Propulsion 
54 71  86 
 Laryngeal Excursion 46 50  50 
Crico-
esophageal 
Bolus Propulsion through 
UES 
23 36 50 
 Clearance of Pyriform Sinus 
Residual 
31 43  50 
 Upper Esophageal Parameters 0 0 0 
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Table 4. Frequency count of penetration-aspiration events across time points 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Pre-
treatment 
% (n) 
4-6 weeks 
post-
treatment 
% (n) 
6 months 
post-
treatment 
% (n) 
Penetration-
Aspiration 
Scale 
Nil Fluids 92 (12) 71 (10) 86 (12) 
Solids 69 (9) 69 (9) 57(8) 
Penetration Fluids 8 (1) 21 (3) 7 (1) 
Solids 23 (3) 23 (3) 29 (4) 
Aspiration Fluids 0 7 (1) 7 (1) 
Solids 8 (1) 8 (1) 14 (2) 
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Table 5. Patient-Generated Subjective Global Assessment (PG-SGA) score and weight from 
pre-treatment to 6 months post-treatment 
 
 Pre-
treatment  
m (SD) 
4-6 wks 
post-
treatment  
m (SD) 
6 mths post-
treatment  
m (SD) 
Statistic p 
Weight (kg) 83.2 (22.72) 73.1 (17.88) 71.4 (17.61) 0.75 λ <0.01 
PG-SGA 
(numerical) 
3.7 (3.25) 10.3 (5.31) 4.8 (3.79) 0.66 p <0.01 
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Table 6. Participant-rated functional impact scores as defined by the MDADIa and FACT-H&Nb from pre-treatment to 6 months post-treatment 
 Quality of 
Life 
Measure 
Pre-treatment  
 
m (SD) 
4-6 wks 
post-
treatment  
m (SD) 
6 mths post-
treatment  
m (SD) 
Friedman Post-hoc Wilcoxon 
 Pre versus 4-6 
weeks 
Pre versus 
6mths 
4-6 weeks 
versus 6mths 
p 
 
Z p Z p Z p 
MDADI Global   76.9 (22.87) 50.8 (22.53) 67.7 (22.42) 0.03 -2.33 0.02 -1.03 0.30 -2.16 0.03 
 Emotional    82.3 (13.69) 73.1 (18.58) 76.4 (18.28) 0.08       
 Functional 83.7 (13.71) 68.0 (20.0) 77.2 (14.46) 0.03 -2.59 0.01 -1.43 0.15 -1.74 0.08 
 Physical 76.0 (20.14) 58.1 (21.46) 68.8 (12.48) 0.06       
            
FACT-H&N Physical 23.8 (4.67) 18.7 (6.92) 21.23 (6.21) <0.01 -2.67 <0.01 -2.21 0.03 -1.97 0.049 
 Social/ 
Family 
22.44 (5.99) 20.1 (6.77) 20.6 (7.59) 0.94       
 Emotional 19.0 (4.0) 18.7 (4.21) 20.6 (2.39) 0.22       
 Functional 20.0 (6.98) 13.8 (6.28) 17.9 (6.63) 0.02 -2.59 0.01 -1.31 0.19 -2.28 0.02 
 Head/Neck 
Specific 
37.1 (6.15) 27.2 (7.22) 29.8 (6.79) <0.01 -2.97 <0.01 -2.75 <0.01 -1.23 0.22 
 Overall 122.5 (21.29) 96.2 (17.86) 111.0 (20.73) 0.03 -2.82 <0.01 -1.92 0.06 -2.42 0.02 
a MDADI = M. D. Anderson Dysphagia Inventory 
b FACT-H&N = Functional Assessment of Cancer Therapy – Additional Concerns for Head and Neck Cancer 
 
 
 
 
